1. Home
  2. FIEE vs CLGN Comparison

FIEE vs CLGN Comparison

Compare FIEE & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiEE Inc

FIEE

FiEE Inc

HOLD

Current Price

$4.56

Market Cap

23.0M

Sector

Utilities

ML Signal

HOLD

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

HOLD

Current Price

$1.93

Market Cap

18.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIEE
CLGN
Founded
N/A
2004
Country
United States
Israel
Employees
43
N/A
Industry
Telecommunications Equipment
Industrial Specialties
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.0M
18.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FIEE
CLGN
Price
$4.56
$1.93
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$11.50
AVG Volume (30 Days)
N/A
28.9K
Earning Date
N/A
11-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,475,000.00
Revenue This Year
N/A
$1,596.12
Revenue Next Year
N/A
$85.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
280.77
52 Week Low
N/A
$1.30
52 Week High
N/A
$4.98

Technical Indicators

Market Signals
Indicator
FIEE
CLGN
Relative Strength Index (RSI) 74.42 65.29
Support Level $3.39 $1.40
Resistance Level $3.70 $1.74
Average True Range (ATR) 0.28 0.15
MACD 0.08 0.05
Stochastic Oscillator 81.53 94.35

Price Performance

Historical Comparison
FIEE
CLGN

About FIEE FiEE Inc

FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: